SEBI Registration No - INA000003197 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS.



Another legal setback for Dr Reddy’s in US

After the gSuboxone halt in US, company has lost out on another blockbuster drug in the US market.

Dr. Reddy’s Laboratories (DRL) has lost a patent infringement case with Eli Lilly and Company in the US District Court regarding a cancer drug Alimta (pemetrexed for injection).

The US District Court for the Southern District of Indiana recently has ruled in favour of Eli Lilly stating that Alimta patents would be get infringed by filers like DRL.

On June 15, the US District Court also favoured Eli Lilly in a litigation battle Vs. Hospira pertaining to the same drug.

Alimta recorded US sales of $2.06bn in 2017 and the patents will expire in May 2022. The loss of patent means a loss of potential blockbuster opportunity for DRL.

This is another legal setback to DRL, which has seen the rollout of gSuboxone being blocked by a court order.

Best services for customers with full technical support make your Financial Trading more easy click here to subscribe us for free >>Bonaz Capital